Comparison of Different Approaches to Predict Metabolic Drug-drug Interactions Publication Comparison of Different Approaches to Predict Metabolic Drug-drug Interactions Three approaches were compared to predict the actual magnitude of drug interaction (the mean fold-change in the area under…Certara2007年10月1日
Prediction of Intestinal First-pass Drug Metabolism Publication Prediction of Intestinal First-pass Drug Metabolism Despite a lower content of many drug metabolising enzymes in the intestinal epithelium compared to…Certara2007年10月1日
Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes Publication Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes An analysis of reported hepatic abundances of CYP3A4 and 3A5 indicated that values determined by…Certara2007年10月1日
A Systematic Comparison of Software Dedicated to Meta-analysis of Causal Studies Publication A Systematic Comparison of Software Dedicated to Meta-analysis of Causal Studies Our objective was to systematically assess the differences in features, results, and usability of currently…Certara2007年9月10日
Modeling, Simulation, and the Critical Path Publication Modeling, Simulation, and the Critical Path The benefits of modeling and simulation fall into two categories: Increased certainty in trial designs…Certara2007年9月6日
Theoretical Assessment of a New Experimental Protocol for Determining Kinetic Values Describing Mechanism (time)-based Enzyme Inhibition Publication Theoretical Assessment of a New Experimental Protocol for Determining Kinetic Values Describing Mechanism (time)-based Enzyme Inhibition We have shown previously that the conventional experimental protocol (CEP) used to characterise mechanism-based enzyme…Certara2007年7月1日
The Use of Mechanistic DM-PK-PD Modeling to Assess the Power of Pharmacogenetic Studies—CYP2C9 and Warfarin as an Example Publication The Use of Mechanistic DM-PK-PD Modeling to Assess the Power of Pharmacogenetic Studies—CYP2C9 and Warfarin as an Example The aim of this study was to assess the power of in vivo studies needed…Certara2007年7月1日
Kinetics of the Time-dependent Inactivation of CYP2D6 in Cryopreserved Human Hepatocytes by Methylenedioxymethamphetamine (MDMA) Publication Kinetics of the Time-dependent Inactivation of CYP2D6 in Cryopreserved Human Hepatocytes by Methylenedioxymethamphetamine (MDMA) Methylenedioxymethamphetamine (MDMA) was investigated in cryopreserved human hepatocytes as a time-dependent inactivator (TDI) of CYP2D6…Certara2007年5月1日
Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX-2 Inhibitor Publication Predictive Population Pharmacokinetic/Pharmacodynamic Model for a Novel COX-2 Inhibitor The objectives of these analyses were to (1) develop a population pharmacokinetic/pharmacodynamic model for a…Certara2007年3月1日
Misuse of the Well-stirred Model of Hepatic Drug Clearance Publication Misuse of the Well-stirred Model of Hepatic Drug Clearance The “well-stirred” model of hepatic drug clearance was first proposed by Gillette and established by…Certara2007年3月1日